Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
about
Immune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumVaccine therapies in malignant gliomaMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsRole of SOX family of transcription factors in central nervous system tumorsCurrent Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible CrosstalkBrain tumor stem cells: Molecular characteristics and their impact on therapyImmunotherapy for brain cancer: recent progress and future promiseStandard chemoradiation for glioblastoma results in progressive brain volume lossOvercoming therapeutic resistance in glioblastoma: the way forwardAdvances in diagnostic and treatment modalities for intracranial tumors.Objective image analysis of real-time three-dimensional intraoperative ultrasound for intrinsic brain tumour surgery.Regulation of stress-inducible phosphoprotein 1 nuclear retention by protein inhibitor of activated STAT PIAS1.Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoGlioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and scienceAnti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patientsRole of AKT signaling in DNA repair and clinical response to cancer therapy.Brevican knockdown reduces late-stage glioma tumor aggressiveness.Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Glioblastoma extracellular vesicles: reservoirs of potential biomarkers.Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma.Glioma-targeting micelles for optical/magnetic resonance dual-mode imaging.Management of high-grade gliomas in the pediatric patient: Past, present, and future.The challenges and the promise of molecular targeted therapy in malignant gliomas.Metformin inhibits growth of human glioblastoma cells and enhances therapeutic responseHigh expression of N-myc (and STAT) interactor predicts poor prognosis and promotes tumor growth in human glioblastoma.Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats.Lack of ROS1 Gene Rearrangement in Glioblastoma MultiformeTumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastomaPromising potency of retinoic acid-poly(ethylene glycol)-thiol gold nanoparticle conjugates for cervical cancer treatment.PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.Fungal metabolite ophiobolin A as a promising anti-glioma agent: In vivo evaluation, structure-activity relationship and unique pyrrolylation of primary amines.Immune phenotypes predict survival in patients with glioblastoma multiforme.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMAThe role of checkpoints in the treatment of GBMMir-338-3p Inhibits Malignant Biological Behaviors of Glioma Cells by Targeting MACC1 Gene.Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells.Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.Role of WW domain proteins WWOX in development, prognosis, and treatment response of glioma.
P2860
Q26765459-E12C76C2-EAE3-436C-AA5E-78A8120D8220Q26829328-A7E9E807-420B-40D8-9207-AF97E17ED11EQ26853516-95D778E9-8311-4302-84B3-4B35BE12B89DQ26860974-065188DC-C185-4101-94D0-809C4CD7F2FDQ26865911-C69EED0A-03C4-46F7-9773-E79031129E2EQ27003138-01DBA159-607B-4254-813D-8CA071DB9605Q27015881-87D999AE-03E5-4BC4-91FE-1BEB8A7D0D40Q27348869-EF7CA1C0-3BFC-4DC5-975C-E6DE85524E56Q29248396-AA54170B-C072-4EC7-B7EF-6E11600EC3EBQ30358150-074BF849-DB2B-4A55-906C-B93BF9B283D1Q30362863-9C9307A7-1BF3-4D31-853E-197F91CE466FQ30409858-6A8C21A3-8510-4511-84D8-0A977EB2CC06Q33720256-52737F2D-3717-40A8-8343-8ED2A5E937D5Q33746514-BD3BA36F-31CA-4202-AC4D-7E546EFCC025Q33795137-3A6CD240-1C3B-43A8-8009-8D7AEB001B17Q34117487-C4982C09-469E-4BEF-936F-EC8B86A6647DQ34193741-DC998C65-5C47-47E3-800E-6F70E24BF13FQ34257738-DEE22474-FAD8-4FA9-8D19-724B66BE7594Q34434111-2024AB05-34FD-48F7-8DA2-71D4D69A63B9Q34818301-6BA1A4F8-87C5-4C8A-80A7-0F9779ADD39CQ35122209-114BD3EE-3455-4310-8EB8-4048964F0E9FQ35152197-A746816E-4817-4692-9957-F94F9CA06F89Q35168731-8041FFC2-C442-48BC-B66D-2DA14375CA05Q35206259-F8EF1885-73C4-454C-AE19-5CD80F3C7F6DQ35214534-2602E010-037F-412F-9767-DDBCAA2F61A4Q35600122-FDF7AEF4-2BBE-4C8F-8BBB-07569CC80CABQ35741574-DFEB2EB3-F9BA-422C-9610-8D6DFDE7EED1Q35742353-E3907515-8AAC-4486-80D4-B922AE6FC607Q35772397-7E3742ED-6E30-4BD3-9B1D-5083EC6424E6Q35970661-56514AEE-0FB0-49E6-A6BC-3FCFDEFCEFA9Q36046125-773599C7-2324-449D-964A-440A87C6A03BQ36086507-06F2976B-DEFD-4A04-9F77-52AB9F93BAA1Q36119458-69F69608-4CBA-40B2-ACD5-71DE2809B537Q36120388-02A4D460-9223-4783-A4E2-B54B50F6D396Q36549443-DD568A7C-7A07-461E-A480-946E270D845CQ36571197-9EB148E4-73A9-4AEE-A100-8914755106A8Q36657798-D8E2C30B-D51E-47EF-A5C3-1A3085D4CE8BQ37013289-53EF887F-66EB-4C56-A970-7241D0BDA93BQ37022278-368F057C-8D59-4455-877B-DE7F2D888E0AQ37071045-A51587EE-D5D5-46CC-807D-C6445B33062C
P2860
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
@en
type
label
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
@en
prefLabel
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
@en
P2093
P2860
P1476
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
@en
P2093
David N Louis
Jorg Dietrich
Shota Tanaka
Tracy T Batchelor
William T Curry
P2860
P356
10.1038/NRCLINONC.2012.204
P407
P577
2012-11-27T00:00:00Z